The therapies that worked, and the numbers that got them through FDA review. Use these as precedents when you design endpoints, choose a cell source or plan a customized product.
Gene-corrected stem cellsFDA-approved
exagamglogene autotemcel
Sickle cell disease and transfusion-dependent beta-thalassemia (age 2+ since Jul 2026)
29 of 31free of severe sickle cell crises for 12+ months
The patient's own blood stem cells are edited with CRISPR/Cas9 and returned once. 29 of 31 evaluable adults and teens had no severe crises for at least 12 months. In children 5–11, 8 of 8 with sickle cell were crisis-free and 8 of 9 with thalassemia stopped transfusions.
Why it matters: First CRISPR medicine in the US: proof that a fully personalized, edited stem cell product can clear FDA.
- Approved
- Dec 8, 2023 (SCD); Jan 16, 2024 (TDT); Jul 1, 2026 (age 2+)
- Evidence
- Single-arm
- Cell source
- Autologous (patient's own cells)
- Safety
- No boxed warning. Requires chemotherapy conditioning (low blood counts, mouth sores, febrile neutropenia).
FDA: first gene therapies for sickle cell disease ↗Gene-corrected stem cellsFDA-approved
lovotibeglogene autotemcel
Sickle cell disease with a history of vaso-occlusive events (age 12+)
88%complete resolution of vaso-occlusive events (28 of 32), months 6–18
A lentiviral vector adds a working beta-globin gene to the patient's own stem cells. 28 of 32 patients had no vaso-occlusive events between 6 and 18 months after infusion.
Why it matters: Approved the same day as CASGEVY: two engineering routes (gene addition vs editing) for one disease.
- Approved
- Dec 8, 2023
- Evidence
- Single-arm
- Cell source
- Autologous (patient's own cells)
- Safety
- Boxed warning for blood cancer; lifelong monitoring.
FDA: first gene therapies for sickle cell disease ↗Gene-corrected stem cellsFDA-approved
betibeglogene autotemcel
Beta-thalassemia needing regular transfusions (adults and children)
89%of 41 patients transfusion-independent for 12+ months
One dose of the patient's own gene-modified stem cells. 89% of 41 patients stopped needing red cell transfusions for at least a year with stable hemoglobin.
Why it matters: First cell-based gene therapy for beta-thalassemia, each dose made from one patient's own marrow.
- Approved
- Aug 17, 2022
- Evidence
- Single-arm
- Cell source
- Autologous (patient's own cells)
- Safety
- No boxed warning; possible blood cancer risk (none seen); monitor 15+ years.
ASCO Post: FDA approves Zynteglo ↗Gene-corrected stem cellsFDA-approved
elivaldogene autotemcel
Early active cerebral adrenoleukodystrophy in boys without a matched donor
72% vs 43%alive without major disability at 24 months, treated vs untreated
The boy's own stem cells receive a working ABCD1 gene. At 24 months, 72% of treated boys were alive without major functional disability versus 43% in natural-history patients.
Why it matters: The clearest example of risk emerging years after approval: long-term follow-up matters.
- Approved
- Sep 16, 2022 (accelerated); restricted Aug 2025
- Evidence
- Natural-history control
- Cell source
- Autologous (patient's own cells)
- Safety
- Boxed warning: blood cancers rose from 3 of 67 to 10 of 67 by July 2025; FDA limited use to boys with no matched donor.
FDA: labeling changes for hematologic malignancy risk ↗Gene-corrected stem cellsFDA-approved
atidarsagene autotemcel
Metachromatic leukodystrophy (MLD) in children
100% vs 58%alive at age 6, treated vs untreated (presymptomatic late infantile)
The child's stem cells get a working ARSA gene. Across 37 treated children, severe motor impairment or death fell sharply; 71% walked unaided at age 5 and 85% had normal language and IQ scores.
Why it matters: Works when given before symptoms: makes the case for newborn screening.
- Approved
- Mar 18, 2024
- Evidence
- Natural-history control
- Cell source
- Autologous (patient's own cells)
- Safety
- No boxed warning; no blood cancers seen. Monitor 15+ years.
FDA: first gene therapy for children with MLD ↗Gene-corrected stem cellsFDA-approved
etuvetidigene autotemcel
Wiskott-Aldrich syndrome (age 6 months+, no matched related donor)
−93%severe infections, months 6–18 vs year before treatment
Gene-corrected stem cells from 27 patients. Severe infections fell 93% and moderate-to-severe bleeding fell 60%; most patients were bleed-free at 4 years.
Why it matters: Developed by a non-profit (Fondazione Telethon): an alternative sponsor model for ultra-rare disease.
- Approved
- Dec 9, 2025
- Evidence
- Single-arm
- Cell source
- Autologous (patient's own cells)
- Safety
- No boxed warning reported. Rash, respiratory infection, febrile neutropenia, liver injury.
FDA: first gene therapy for Wiskott-Aldrich syndrome ↗Gene-corrected stem cellsFDA-approved
marnetegragene autotemcel
Severe leukocyte adhesion deficiency type I in children without a matched sibling donor
100%survival without transplant at 1 year (9 children; 95% CI 66–100)
Stem cells corrected with the ITGB2 gene. All children enrolled before age 1 were alive past age 2. FDA's accelerated approval rests on restored CD18/CD11a on white cells at 12 months, sustained to 24 months.
Why it matters: Accelerated approval on a biomarker with only 9 patients: a template for ultra-rare indications.
- Approved
- Mar 26, 2026 (accelerated)
- Evidence
- Single-arm
- Cell source
- Autologous (patient's own cells)
- Safety
- No boxed warning reported. Confirmatory evidence required for full approval.
FDA: first gene therapy for LAD-I ↗Blood & immune rebuildFDA-approved
Orca-T; regulatory T cells with HSPCs and T cells
Adults with blood cancers having matched-donor transplant
78% vs 38%1-year survival free of moderate-to-severe chronic GVHD
A precision-engineered donor graft tested against a standard transplant in 187 adults with acute leukemia or MDS (Precision-T). Chronic GVHD fell from 44% to 13% (HR 0.26); overall survival was 93.9% vs 83.1%, not statistically significant.
Why it matters: Strongest randomized win among stem/progenitor products.
- Approved
- Jun 30, 2026
- Evidence
- Randomized
- Cell source
- Allogeneic (donor cells)
- Safety
- Warnings: graft failure, GVHD, infusion reactions, secondary cancers. List price $428,000.
CancerNetwork: FDA OKs regulatory T-cell immunotherapy ↗Blood & immune rebuildFDA-approved
omidubicel-onlv
Blood cancers needing cord blood transplant (age 12+); severe aplastic anemia (Dec 2025)
12 vs 22 daysmedian neutrophil recovery vs standard cord blood
Cord blood expanded with nicotinamide, tested against standard cord blood in 125 patients. White cells recovered faster and serious infections by day 100 fell from 60% to 39%.
Why it matters: Expanded cord blood widens donor options for patients without a matched adult donor.
- Approved
- Apr 17, 2023
- Evidence
- Randomized
- Cell source
- Allogeneic (donor cells)
- Safety
- Boxed warning: infusion reactions, GVHD, engraftment syndrome, graft failure.
FDA approval via BioSpace ↗Blood & immune rebuildFDA-approved
remestemcel-L-rknd
Steroid-refractory acute GVHD in children (2 months+)
70%overall response at day 28 (54 children)
Donor bone-marrow mesenchymal stromal cells in 54 children, 89% with grade C/D disease. 30% had complete and 41% partial responses by day 28.
Why it matters: The only FDA-approved MSC product, reached after rejections in 2020 and 2023 over potency assays.
- Approved
- Dec 18, 2024
- Evidence
- Single-arm
- Cell source
- Allogeneic (donor cells)
- Safety
- No boxed warning. Label warnings: hypersensitivity and infusion reactions, transmission of infectious agents, ectopic tissue formation.
FDA: RYONCIL prescribing information ↗Blood & immune rebuildFDA-approved
HEMACORD, DUCORD, ALLOCORD, CLEVECORD, REGENECYTE and 4 more
Unrelated-donor transplant to rebuild blood and immune function
9public and commercial cord blood banks licensed
FDA licensed cord blood from New York Blood Center, ClinImmune, Duke, Cardinal Glennon, LifeSouth, Bloodworks, Cleveland, MD Anderson and StemCyte on existing transplant outcome data, without new trials.
Why it matters: The oldest licensed stem cell product class in the US, and the first commercial license (StemCyte) came only in 2024.
- Approved
- Nov 2011 (HEMACORD) to Nov 2024 (REGENECYTE)
- Evidence
- Legacy registry data
- Cell source
- Allogeneic (donor cells)
- Safety
- Boxed warning: fatal infusion reactions, GVHD, engraftment syndrome and graft failure.
FDA: cord blood products FAQ ↗Blood & immune rebuildFDA-approved
allogeneic processed thymus tissue-agdc
Congenital athymia in children
77%survival at 1 year (76% at 2 years)
Children born without a thymus usually die by age 2–3. Across 105 children, implanted donor thymus gave 77% survival at 1 year, and 94% of 1-year survivors were alive at a median 10.7 years.
Why it matters: Dose is sized to each child's body surface area: early patient-customized tissue dosing.
- Approved
- Oct 8, 2021
- Evidence
- Natural-history control
- Cell source
- Allogeneic (donor cells)
- Safety
- Hypertension, cytokine release, rash, low platelets, GVHD.
Medthority: Rethymic approval data ↗Engineered immune cellsFDA-approved
tisagenlecleucel
B-cell acute lymphoblastic leukemia (ALL) up to age 25; DLBCL; follicular lymphoma
83%remission within 3 months (63 patients, ELIANA)
The patient's own T cells engineered with a CD19 CAR. 83% of children and young adults with relapsed leukemia went into remission.
Why it matters: First CAR-T and first gene therapy approved in the US.
- Approved
- Aug 30, 2017 (first CAR-T)
- Evidence
- Single-arm
- Cell source
- Autologous (patient's own cells)
- Safety
- Boxed warning: cytokine release syndrome, neurotoxicity, secondary T-cell cancers.
NCI: tisagenlecleucel approval ↗Engineered immune cellsFDA-approved
axicabtagene ciloleucel
Large B-cell lymphoma (2nd line+); follicular lymphoma
8.3 vs 2.0 momedian event-free survival vs standard care (ZUMA-7, n=359)
In a randomized trial against standard chemotherapy and transplant, CAR-T cut the risk of an event by 60% (HR 0.40); response rate 83% vs 50%.
Why it matters: Moved CAR-T earlier in treatment by beating standard of care head-to-head.
- Approved
- Oct 18, 2017; 2nd line Apr 1, 2022
- Evidence
- Randomized
- Cell source
- Autologous (patient's own cells)
- Safety
- Boxed warning: CRS (90%), neurotoxicity (78%), secondary T-cell cancers.
ASCO Post: axi-cel second-line approval ↗Engineered immune cellsFDA-approved
brexucabtagene autoleucel
Mantle cell lymphoma; adult B-cell acute lymphoblastic leukemia
87%response rate in mantle cell lymphoma (60 evaluable, ZUMA-2)
CD19 CAR-T for relapsed mantle cell lymphoma after BTK inhibitors: 62% complete remissions. The accelerated approval was converted to full approval in 2026. Also approved for adult acute lymphoblastic leukemia.
Why it matters: First CAR-T for mantle cell lymphoma.
- Approved
- Jul 24, 2020 (MCL, accelerated; full approval 2026); adult ALL later
- Evidence
- Single-arm
- Cell source
- Autologous (patient's own cells)
- Safety
- Boxed warning: CRS, neurotoxicity, secondary T-cell cancers.
ONS: FDA approves brexucabtagene autoleucel ↗Engineered immune cellsFDA-approved
lisocabtagene maraleucel
Large B-cell, follicular, mantle cell and marginal zone lymphoma; CLL/SLL
84.4%response rate in marginal zone lymphoma (77 patients)
A CD19 CAR-T with a defined CD8:CD4 mix, now approved across six B-cell cancers. In marginal zone lymphoma, 55.8% had complete responses.
Why it matters: Broadest CAR-T label: one product expanded through many single-indication trials.
- Approved
- Feb 5, 2021; marginal zone Dec 4, 2025
- Evidence
- Single-arm
- Cell source
- Autologous (patient's own cells)
- Safety
- Boxed warning: CRS, neurotoxicity, secondary T-cell cancers.
ASCO Post: liso-cel for marginal zone lymphoma ↗Engineered immune cellsFDA-approved
idecabtagene vicleucel
Relapsed/refractory multiple myeloma
13.3 vs 4.4 momedian progression-free survival vs standard regimens (KarMMa-3)
First BCMA CAR-T. In 386 randomized patients, it more than doubled progression-free survival (HR 0.49); response 71% vs 42%.
Why it matters: First cell therapy for myeloma.
- Approved
- Mar 26, 2021; 3rd line Apr 4, 2024
- Evidence
- Randomized
- Cell source
- Autologous (patient's own cells)
- Safety
- Boxed warning: CRS, neurotoxicity, HLH/MAS, prolonged low blood counts, secondary T-cell cancers.
ASCO Post: cilta-cel and ide-cel approvals ↗Engineered immune cellsFDA-approved
ciltacabtagene autoleucel
Relapsed/refractory multiple myeloma (lenalidomide-refractory, 2nd line+)
HR 0.55risk of death vs standard care (CARTITUDE-4)
In 419 randomized patients, BCMA CAR-T cut progression risk by 71% (HR 0.29) and death risk by 45% at 33.6 months.
Why it matters: Clearest overall-survival benefit for any CAR-T.
- Approved
- Feb 28, 2022; 2nd line Apr 5, 2024
- Evidence
- Randomized
- Cell source
- Autologous (patient's own cells)
- Safety
- Boxed warning: CRS, neurotoxicity incl. parkinsonism and Guillain-Barré, HLH, low blood counts, secondary cancers.
ASCO Post: CARTITUDE-4 updated analysis ↗Engineered immune cellsFDA-approved
obecabtagene autoleucel
Adult relapsed/refractory B-cell acute lymphoblastic leukemia
42%complete remission within 3 months (27 of 65)
A CD19 CAR with a fast off-rate binder designed to lower toxicity; median remission lasted 14.1 months.
Why it matters: Shows CAR design can trade some potency for much lower toxicity.
- Approved
- Nov 8, 2024
- Evidence
- Single-arm
- Cell source
- Autologous (patient's own cells)
- Safety
- Severe CRS only 3% and severe ICANS 7%; no REMS required.
ASCO Post: obe-cel approval ↗Engineered immune cellsFDA-approved
lifileucel
Advanced melanoma after anti-PD-1 therapy
31.5%response rate (of 73 patients)
Tumor-infiltrating lymphocytes grown from the patient's own tumor. About 1 in 3 patients whose melanoma had failed immunotherapy responded, many durably.
Why it matters: First cell therapy for a solid tumor, made from the patient's own tumor.
- Approved
- Feb 16, 2024 (accelerated)
- Evidence
- Single-arm
- Cell source
- Autologous (patient's own cells)
- Safety
- Boxed warning: treatment-related death, prolonged cytopenia, severe infection, organ impairment.
FDA: lifileucel accelerated approval ↗Engineered immune cellsFDA-approved
afamitresgene autoleucel
Metastatic synovial sarcoma (HLA-A*02, MAGE-A4 positive)
43.2%response rate (44 patients infused)
T cells engineered with a MAGE-A4 T-cell receptor. 39% of responders were still responding at 12 months.
Why it matters: First engineered TCR therapy: patient selection by HLA type is built into the label.
- Approved
- Aug 2, 2024 (accelerated)
- Evidence
- Single-arm
- Cell source
- Autologous (patient's own cells)
- Safety
- Boxed warning: serious or fatal cytokine release syndrome.
FDA: afami-cel accelerated approval ↗Engineered immune cellsFDA-approved
sipuleucel-T
Metastatic castration-resistant prostate cancer
25.8 vs 21.7 momedian overall survival vs placebo (IMPACT, n=512)
The patient's own antigen-presenting cells are activated and returned. It reduced risk of death by 22% (HR 0.78) without slowing measured progression.
Why it matters: First autologous cell therapy approved, and still the only one approved on an overall-survival endpoint.
- Approved
- Apr 29, 2010
- Evidence
- Randomized
- Cell source
- Autologous (patient's own cells)
- Safety
- Infusion reactions; no boxed warning reported.
NEJM IMPACT trial (PubMed) ↗Tissue & organ repairFDA-approved
donislecel
Type 1 diabetes with repeated severe hypoglycemia (adults)
21 of 30insulin-free for a year or more
Donor pancreatic islets infused into the liver. 21 of 30 needed no insulin for at least a year, and 10 stayed insulin-free more than five years.
Why it matters: First cell therapy for type 1 diabetes and the precedent for stem-cell-derived islets.
- Approved
- Jun 28, 2023
- Evidence
- Single-arm
- Cell source
- Allogeneic (donor cells)
- Safety
- Lifelong immunosuppression; procedure risks.
BioSpace: first cell therapy for T1D ↗Tissue & organ repairFDA-approved
prademagene zamikeracel
Wounds in recessive dystrophic epidermolysis bullosa
81% vs 16%wounds 50%+ healed at 6 months, treated vs control
The patient's own skin cells are gene-corrected to make type VII collagen and grafted as sheets. 43 wound pairs were compared within the same patients.
Why it matters: A one-time, patient-specific surgical product with healing seen up to 8 years.
- Approved
- Apr 29, 2025
- Evidence
- Intrapatient control
- Cell source
- Autologous (patient's own cells)
- Safety
- No treatment-related serious adverse events.
Drugs.com: FDA approves Zevaskyn ↗Tissue & organ repairFDA-approved
autologous cultured chondrocytes on porcine collagen membrane
Full-thickness knee cartilage defects (adults). Not approved for osteoarthritis or general knee arthritis
5 yearsbenefit sustained vs microfracture (128 of 144 followed)
The patient's own cartilage cells are grown on a membrane and implanted. In 144 randomized patients (72 per arm), KOOS pain rose from 37.0 to 82.5 with MACI, significantly more than with microfracture at 2 years.
Why it matters: One of the few cell products with a randomized surgical comparator and 5-year data.
- Approved
- Dec 2016
- Evidence
- Randomized
- Cell source
- Autologous (patient's own cells)
- Safety
- Joint pain, graft overgrowth; porcine/bovine allergy contraindication.
SUMMIT 5-year results (PubMed) ↗Tissue & organ repairFDA-approved
allogeneic keratinocytes and fibroblasts in murine collagen
Deep partial-thickness thermal burns (adults)
96%of sites spared an autograft donor wound (68 of 71)
Lab-grown donor skin compared with the patient's own skin graft in the same patient. Durable wound closure at 3 months was 83% vs 86%.
Why it matters: Success defined practically: nearly as good as an autograft without a second wound.
- Approved
- Jun 2021
- Evidence
- Intrapatient control
- Cell source
- Allogeneic (donor cells)
- Safety
- Itching 11%; xenotransplant rules mean patients cannot donate blood or tissue.
FDA: StrataGraft label ↗Tissue & organ repairFDA-approved
revakinagene taroretcel-lwey
Macular telangiectasia type 2 (adults)
54.8%slower photoreceptor loss vs sham (trial 1; 30.6% in trial 2)
An encapsulated cell implant in the eye that releases CNTF. Two sham-controlled trials in 228 patients both met their 24-month endpoint.
Why it matters: First encapsulated-cell therapy approved; the capsule shields donor cells from the immune system.
- Approved
- Mar 2025
- Evidence
- Randomized
- Cell source
- Allogeneic (donor cells)
- Safety
- Delayed dark adaptation (~20%) and small pupils (~15%).
NEI: long-term benefit of implant ↗Tissue & organ repairFDA-approved
acellular tissue engineered vessel-tyod
Extremity arterial injury needing urgent bypass (adults)
84.3%vessels open at day 30 (43 of 51)
A vessel grown from donor cells and then decellularized. Amputation was 9.8% and graft infection 2% in trauma patients, compared with published synthetic-graft rates of 24.3% and 8.4%.
Why it matters: Cells as a manufacturing tool: the final product contains no living cells.
- Approved
- Dec 19, 2024
- Evidence
- Single-arm
- Cell source
- Allogeneic (donor cells)
- Safety
- Graft rupture and thrombosis warnings.
JAMA Surgery: V005 trial ↗Tissue & organ repairFDA-approved
azficel-T
Moderate-to-severe nasolabial fold wrinkles (adults)
421patients in two randomized, placebo-controlled phase 3 trials
The patient's own cultured skin fibroblasts, injected in three sessions about five weeks apart. Approval followed a complete response letter and an added skin-biopsy safety study.
Why it matters: First personalized aesthetic cell therapy approved by FDA.
- Approved
- Jun 21, 2011
- Evidence
- Randomized
- Cell source
- Autologous (patient's own cells)
- Safety
- Injection-site reactions.
Fibrocell: FDA approval of LAVIV ↗Tissue & organ repairFDA-approved
allogeneic keratinocytes and fibroblasts in bovine collagen
Gum tissue repair in mucogingival surgery (adults)
≥50%of patients gained 2 mm+ of keratinized gum tissue
A donor-cell dressing that regrows gum tissue without harvesting tissue from the patient's palate. In each of two studies, at least half of patients gained 2 mm or more; 121 subjects in total.
Why it matters: First allogeneic cell product for dentistry.
- Approved
- Mar 9, 2012
- Evidence
- Intrapatient control
- Cell source
- Allogeneic (donor cells)
- Safety
- Sinusitis, mouth ulcers, local pain.
FDA press release (archived) ↗Next wave (investigational)Investigational
stem cell-derived islets (Vertex)
Type 1 diabetes with impaired hypoglycemia awareness
10 of 12insulin-free at one year (full dose)
Islets grown from pluripotent stem cells. In the Oct 2026 update all 12 had HbA1c below 7%, and time in target range rose from 49.5% to 93.3%.
Why it matters: A manufactured islet supply could end the donor-pancreas bottleneck.
- Data
- NEJM 2025; update Oct 2026
- Evidence
- Single-arm
- Cell source
- Allogeneic (donor cells)
- Safety
- Chronic immunosuppression; 2 deaths reported as unrelated. Phase 3 enrolling; no US filing confirmed.
MedCity: zimislecel results ↗Next wave (investigational)Investigational
hypoimmune gene-edited donor islets
Type 1 diabetes, without immunosuppression
12 monthsislets evaded immune attack with no immunosuppressants (n=1)
Edited donor islets injected into muscle survived and made insulin with no anti-rejection drugs. Insulin output roughly halved between months 6 and 12; the low dose did not make the patient insulin-free.
Why it matters: The first human evidence that cells can be engineered to avoid rejection.
- Data
- First-in-human, 12-month data 2026
- Evidence
- Case series
- Cell source
- Allogeneic (donor cells)
- Safety
- No drug-related adverse events; durability unproven.
JDCA: Sana 1-year UP421 results ↗Next wave (investigational)Investigational
embryonic stem cell-derived dopamine neuron progenitors
Parkinson's disease
−23 ptsMDS-UPDRS Part III OFF score, high dose (7 of 12 patients)
Twelve patients received grafts; there were no product-related serious adverse events or graft-induced dyskinesias, and the graft survived on PET. A sham-controlled phase 3 (exPDite-2) is enrolling.
Why it matters: Furthest-advanced pluripotent stem cell therapy for the brain in the US.
- Data
- Nature 2025; 36-month data 2026
- Evidence
- Single-arm
- Cell source
- Allogeneic (donor cells)
- Safety
- 12 months of immunosuppression; RMAT designation.
Nature 2025: Phase I trial (PubMed) ↗Next wave (investigational)Investigational
iPS cell-derived dopamine progenitors (raguneprocel)
Parkinson's disease
+35.7%motor score improvement ON medication at 24 months
Seven patients received reprogrammed-stem-cell neurons. Cells survived, produced dopamine and formed no tumors; 5 of 6 improved ON medication.
Why it matters: First iPS-cell therapy approved anywhere (conditionally, Japan).
- Data
- Nature Apr 2025; Japan conditional approval Mar 6, 2026
- Evidence
- Single-arm
- Cell source
- Allogeneic (donor cells)
- Safety
- Not FDA-approved; Japan approval is conditional on very small, uncontrolled data.
PMLive: Sumitomo limited approval in Japan ↗Next wave (investigational)Investigational
embryonic stem cell-derived inhibitory interneurons
Drug-resistant temporal lobe epilepsy
89%median seizure reduction (low-dose group)
A one-time implant of calming neurons. 7 of 9 low-dose patients halved their seizures at months 7–12.
Why it matters: A cell therapy aimed at restoring brain circuits rather than replacing lost cells.
- Data
- AAN 2026 data
- Evidence
- Single-arm
- Cell source
- Allogeneic (donor cells)
- Safety
- Company-reported, open-label. RMAT; sham-controlled Phase 3 starting 2H 2026.
Neurona AAN 2026 update ↗Next wave (investigational)Investigational
autologous CD19 CAR-T
Lupus, myositis, systemic sclerosis
15 of 15off all immunosuppressive drugs
All 8 lupus patients reached drug-free remission; myositis and systemic sclerosis patients also improved.
Why it matters: Points to an immune 'reset' for autoimmune disease.
- Data
- NEJM 2024; long-term series
- Evidence
- Case series
- Cell source
- Autologous (patient's own cells)
- Safety
- Mostly mild cytokine release; industry trials under way.
CGTLive: CAR-T in autoimmune disease ↗Next wave (investigational)Investigational
CAR mRNA in T-cell-targeted lipid nanoparticles
Lupus
5patients with B cells cleared, no cell manufacturing
CAR-T made inside the body from an infusion, with no cell collection or manufacturing. Lupus activity scores fell by up to 20 points at 3 months.
Why it matters: Could make customized cell therapy deliverable outside specialized centers.
- Data
- NEJM, Oct 2025
- Evidence
- Case series
- Cell source
- Autologous (patient's own cells)
- Safety
- No severe cytokine release; very early.
MagicRNA NEJM publication ↗Next wave (investigational)Investigational
embryonic stem cell-derived retinal pigment epithelium
Geographic atrophy (dry AMD)
+6.2 lettersvision gain at 36 months (10 eyes)
Subretinal stem-cell-derived support cells; eyes with the most coverage gained 9.0 letters.
Why it matters: Durable vision gains from a one-time cell transplant.
- Data
- 36-month data 2026
- Evidence
- Single-arm
- Cell source
- Allogeneic (donor cells)
- Safety
- Open-label; Phase 2a GAlette enrolling.
Retinal Physician: OpRegen ↗Next wave (investigational)Investigational
allogeneic donor stem cells, mostly CCR5Δ32
HIV in people transplanted for blood cancer
~10people cured or in long-term remission
Berlin, London, Düsseldorf, City of Hope, New York, Geneva, Oslo and others. The Geneva case had no protective mutation.
Why it matters: Proof that replacing the immune system with stem cells can cure HIV.
- Data
- Case reports 2009–2026
- Evidence
- Case series
- Cell source
- Allogeneic (donor cells)
- Safety
- Not scalable: transplant is done only for cancer.
aidsmap: two more people may be cured ↗